Immodulator Peptide Covalent Modification for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide-based drug development faces challenges such as limited potency, targeting scope, solubility, and bioavailability issues, along with high development costs and stringent regulatory requirements, which have led to a shortage of new drug candidates.
Innovation Solution
The development of chemically modified immodulator peptides with covalently attached small molecules and metal or glycosaminoglycan complexes, expanding the range of biological activities and improving therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immodulator peptides are chemically modified with small molecules and metal complexes, then therapeutic efficacy and stability are improved, but manufacturing complexity and cost increase
Solution Approach 1:
The peptide modification process is divided into distinct segments: core peptide synthesis, N-terminal modification with small molecules, and metal complex formation. This segmentation allows each step to be optimized independently, improving manufacturing feasibility while maintaining therapeutic efficacy.
Solution Approach 2:
The patent modifies physical and chemical parameters of the peptide including molecular weight (through small molecule attachment), solubility (improved by hydrophilic modifications), and stability (enhanced by metal complex formation). These parameter changes resolve the contradiction by improving therapeutic properties while keeping modifications within controllable ranges.
2Stability of the object's composition
If immodulator peptides are chemically modified with small molecules and metal complexes, then stability and solubility are improved, but manufacturing cost increases
Solution Approach 1:
The peptide modifications are designed to be self-stabilizing through inherent chemical properties. Metal complexes and small molecules attach to the N-terminus and provide structural stability and solubility enhancement without requiring additional stabilization agents or complex formulation processes, thereby reducing manufacturing costs.
Solution Approach 2:
The patent creates composite structures by combining the peptide core with small molecules and metal complexes. This composite approach improves stability and solubility through the synergistic properties of the combined materials, while the modular nature allows for cost-effective production through established chemical synthesis methods.
3Adaptability or versatility
If immodulator peptides are chemically modified, then targeting scope and biological activity are expanded, but regulatory approval difficulty increases
Solution Approach 1:
The N-terminal modification platform provides multi-functionality by enabling the same core peptide to be adapted for different therapeutic targets and indications through attachment of various small molecules and metal complexes. This universality simplifies regulatory approval by demonstrating a validated modification platform rather than requiring separate approvals for each variant.
Solution Approach 2:
The patent systematically varies chemical parameters (molecular weight, charge, hydrophobicity) through controlled modifications while maintaining the core peptide sequence. This approach allows for expanded targeting scope while keeping changes within predictable ranges that can be more easily evaluated for regulatory approval.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These modifications enhance the stability, solubility, and bioavailability of peptides, allowing for targeted delivery and improved therapeutic effects while reducing immunogenicity concerns, thus addressing multiple technical issues in drug development.
Implementation Method 1
a small molecule of molecular mass less than one thousand daltons linked covalently to the amino terminus of the amino acid sequence
Data Source
AI summary
This invention provides modified IGFBP-derived peptides—collectively termed “immodulator peptides”—and related compositions and methods. Chemical modifications to peptides using small molecules, and sequence extensions to immodulator core sequences exhibit new and surprising biological activities. The invention builds the combinatorial power of the immodulator peptide class further by demonstrating which core sequences bind metal or glycosaminoglycans such as heparin. The invention discloses some surprising biological properties of compositions derived from these modifications, including a host of new therapeutic and diagnostic utilities (e.g. immune modulation of TLR signaling, enhanced collagen synthesis by skin fibroblasts, and synergy with a RIG-I agonist in killing melanoma cells). The invention also teaches methods for enhancing previously disclosed uses of immodulator peptides by showing how the modifications of the invention can boost the efficacy of immodulator peptides in a model of burn trauma.